23. Mai 2025|
AI
|7 months agoNovartis Ventures into Anti-Aging Research with $550M Deal
Swiss pharmaceutical giant Novartis makes strategic move into longevity research through partnership with BioAge Labs, marking significant investment in aging-related drug development.
AI
Generated IllustrationKey Takeaways
AI
- Novartis has entered a partnership with California-based BioAge Labs worth up to $550 million.
- The partnership grants Novartis access to BioAge's data on human longevity rather than a specific drug candidate.
- Novartis established the Diseases of Ageing and Regenerative Medicine (DARe) research group in 2023.
- BioAge possesses exclusive rights to genomic profiles and medical histories tracked for up to 50 years.
By The Numbers
$550 million
Potential Deal Value
2.1 billion
Projected Population Aged 60+
20%
Global Population Share
Triple
Growth Rate
They Said
"Our goal is to understand the biological drivers of ageing to develop novel treatments for diseases related to ageing. The hope is this opens the door to not only treat one illness but tackle entire classes of diseases."
"Data is the new oil."